drugset / Trial / NCT02223026

Relative Bioavailability of a Linagliptin+Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects

NCT02223026

Phase 1 Completed 32 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to investigate the effect of food on the relative bioavailability of a 2.5 mg linagliptin+1000 mg metformin fixed dose combination (FDC) tablet

Timeline

Start
2010-01
Primary completion
2010-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Linagliptin Small molecule 2.5 mg
Subject Metformin Small molecule 1000 mg

Indications

No indication recorded.